Echinacoside Protects against 6-Hydroxydopamine-Induced Mitochondrial Dysfunction and Inflammatory Responses in PC12 Cells via Reducing ROS Production

Yue-Hua Wang, Zhao-Hong Xuan, Shuo Tian, and Guan-Hua Du

1Beijing Key Laboratory of Drug Target Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
3Shenyang Pharmaceutical University, Shenyang 110016, China

Correspondence should be addressed to Yue-Hua Wang; wangyuehua@pku.org.cn and Guan-Hua Du; dugh@imm.ac.cn

Received 12 September 2014; Revised 11 January 2015; Accepted 16 January 2015

1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic (DA) neurons at the substantia nigra. Mitochondrial dysfunction and inflammatory responses are involved in the mechanism of cell damage in PD. 6-Hydroxydopamine (6-OHDA), a dopamine analog, specifically damages dopaminergic neurons. Echinacoside (ECH) is a phenylethanoid glycoside isolated from the stems of Cistanche salsa, showing a variety of neuroprotective effects in previous studies. The present study was to investigate its effect against 6-OHDA-induced neurotoxicity and possible mechanisms in PC12 cells. The results showed that 6-OHDA reduced cell viability, decreased oxidation-reduction activity, decreased mitochondrial membrane potential, and induced mitochondria-mediated apoptosis compared with untreated PC12 cells. However, echinacoside treatment significantly attenuated these changes induced by 6-OHDA. In addition, echinacoside also could significantly alleviate the inflammatory responses induced by 6-OHDA. Further research showed that echinacoside could reduce 6-OHDA-induced ROS production in PC12 cells. These results suggest that the underlying mechanism of echinacoside against 6-OHDA-induced neurotoxicity may involve in attenuating mitochondrial dysfunction and inflammatory responses by reducing ROS production.
underlying mechanisms of echinacoside against 6-OHDA-induced damage in PC12 cells.

2. Materials and Methods

2.1. Materials. Echinacoside was obtained from National Institutes for Food and Drug Control (Beijing, China). RPMI-1640 and fetal bovine serum were obtained from Gibco (Grand Island, NY, USA). 6-OHDA, MTT, 2,7-dichlorodihydrofluorescein diacetate, propidium iodide (PI), and resazurin were purchased from Sigma-Aldrich (St. Louis, MO, USA). The ATP bioluminescent assay kit was obtained from Promega (Madison, USA). 5,5,6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) assay kit was obtained from Beyotime Institute of Biotechnology (Haimen, Jiangsu, China). Cytochrome C ELISA kit and fluorogenic substrate Ac-DEVD-AMC were obtained from Invitrogen (Carlsbad, CA, USA). IL-1β and IL-6 ELISA kits were obtained from Boster Bio-engineer limited company (Wuhan, China). Spectramax M5 microplate reader was purchased from Molecular Devices company (Sunnyvale, CA, USA).

2.2. Cell Culture and Treatment. PC12 cells were grown in RPMI-1640 supplemented with 10% horse serum and 5% fetal bovine serum. Conditions were maintained at 37°C in a humidified atmosphere containing 5% CO₂ [19]. The cells were plated into 96-well plates at a density of 2 x 10⁵ cells/mL. After 80% confluence, the cells were preincubated with different concentrations of echinacoside in a serum-free RPMI-1640 medium for 1 h. Then, 6-OHDA was added to the wells at a final concentration of 100 µM and incubated for another 24 h at 37°C.

2.3. Morphological Changes and Viability Assay of PC12 Cells. After treatment, morphological changes were observed under microscope. Cell viability was evaluated by MTT assay [19]. Briefly, after treatment, MTT at the final concentration of 0.5 mg/mL was added to each well and incubated for 4 h at 37°C. Then, the supernatant was removed and the formazan product was dissolved in 100 µL dimethyl sulfoxide with stirring for 15 min on a microtiter plate shaker and the absorbance was read at 570 nm using a Spectramax M5 microplate reader.

2.4. Intracellular ATP Level Assay. Cellular ATP level was measured with an ATP bioluminescent assay kit according to the manufacturer’s instructions. Luminescence was monitored on a microplate reader in the luminescence mode following the addition 100 µL of luciferin and luciferase [20].

2.5. Measurement of Mitochondria Oxidation-Reduction Activity by Resazurin. After treatment, resazurin at final concentration of 5 µM was added into the wells and fluorescence intensity was examined at an excitation of 530 nm and an emission of 590 nm [21].

2.6. Measurement of Mitochondrial Membrane Potential by JC-1. The mitochondrial membrane potential was measured using JC-1 assay kit according to the manufacturer’s instructions. After treatment, the culture medium was removed and loaded with JC-1 solution for 15 min at 37°C in the dark. The fluorescence intensity of the red/green ratio was determined at an excitation of 490 nm and emission of 530 nm (green fluorescent monomers) and 590 nm (red fluorescent aggregates), respectively [22].

2.7. Quantification of Cytochrome C Release. The cytosolic cytochrome C levels were measured using an ELISA kit according to the manufacturer’s instructions [23]. Briefly, after treatment, the cells were lysed and centrifugated at 1000 g for 15 min, and then the supernatant was collected as cytoplasmic fraction and used for cytochrome C release measurements.

2.8. Determination of Caspase-3 Activity. Caspase-3 activity was performed according to the references with modification [24]. Briefly, after treatment, the lysis buffer was added to each well and followed by centrifugation at 12,000 g for 10 min. Caspase-3 activity was tested in resulting supernatants by measuring the proteolytic cleavage of the fluorogenic substrate Ac-DEVD-AMC with an excitation wavelength of 380 nm and an emission wavelength of 460 nm.

2.9. Flow Cytometry Assay in PC12 Cells. After treatment, cells were trypsinized, washed twice with PBS, centrifuged at 1000 r/min for 5 min, and then fixed with 70% ethanol overnight at 4°C. The cells were centrifuged and washed twice with PBS, resuspended in PBS (containing 50 µg/mL RNaseA), stained with PI at the final concentration of 10 µM for 30 min at room temperature in the dark, and read in a flow cytometer at 488 nm excitation [10].

2.10. Measurement of IL-1β and IL-6 Level by ELISA Assay. The cultured PC12 cells medium was collected after treatment, and the IL-1β and IL-6 concentrations were measured by commercially available ELISA kits according to the manufacturer’s protocol.

2.11. Determination of Intracellular Reactive Oxygen Species Level. After incubation with 6-OHDA, cells were loaded with 10 µM H₂DCFH-DA for 30 min at 37°C in the dark. The fluorescence intensity of DCF was measured at an excitation
wavelength of 495 nm and emission wavelength of 530 nm on a microplate reader [25].

2.12. Statistical Analysis. All data are expressed as the mean ± SD. Statistical analysis of the results was carried out by one-way analysis of variance (ANOVA), followed by t-test. Statistical significance was accepted at \( P < 0.05 \).

3. Results

3.1. Effect of Echinacoside on Morphology and Cell Viability in PC12 Cells Damaged by 6-OHDA. As shown in Figure 2(A), the viability of PC12 cells had no significant difference at the concentration of 0.1–10 \( \mu M \) of echinacoside treatment for 24 h. As shown in Figure 2(B), within 24 h of treatment with 6-OHDA alone, the majority of PC12 cells had undergone morphological changes such as membrane blebbing and cell shrinkage. Cotreatment with echinacoside protected the cells from 6-OHDA damage. MTT assay showed that treatment of PC12 cells with 6-OHDA alone resulted in an approximately 25% reduction in cell survival within 24 h, whereas cotreatment with 0.1 \( \mu M \), 1 \( \mu M \), and 10 \( \mu M \) echinacoside showed a reduction of 6-OHDA-mediated cytotoxicity (all \( P < 0.01 \), Figure 2(C)).

3.2. Effect of Echinacoside on Mitochondria Dysfunction Induced by 6-OHDA in PC12 Cells. Cellular ATP levels were significantly decreased following 24 h incubation with 100 \( \mu M \) 6-OHDA, whereas cotreatment with 1 \( \mu M \) and 10 \( \mu M \) of echinacoside alleviated 6-OHDA-mediated ATP decrease (\( P < 0.05 \) and \( P < 0.01 \), resp.; Figure 3(a)).

Resazurin was used here to detect mitochondrial metabolic changes in PC12 cells. The results showed that cotreatment with 1 \( \mu M \) and 10 \( \mu M \) of echinacoside could significantly attenuate mitochondria oxidation–reduction activity impairment induced by 6-OHDA (both \( P < 0.05 \) and Figure 3(b)).

As shown in Figure 3(c), treatment with 100 \( \mu M \) of 6-OHDA for 24 h resulted in significant decrease of mitochondrial membrane potential compared with untreated group (\( P < 0.01 \)). However, the decrease of mitochondrial membrane potential induced by 6-OHDA was significantly attenuated by cotreatment with 0.1 \( \mu M \), 1 \( \mu M \), and 10 \( \mu M \) of echinacoside (all \( P < 0.01 \)).

3.3. Anti-Mitochondria-Mediated Apoptosis of Echinacoside in PC12 Cells against 6-OHDA Neurotoxicity. The results showed that 6-OHDA exposure resulted in an increase in cytosolic cytochrome C by 167% over the untreated group (\( P < 0.01 \)). Echinacoside at the dose of 0.1 \( \mu M \), 1 \( \mu M \), and 10 \( \mu M \) could significantly reduce the cytochrome C release into cytosol induced by 6-OHDA (\( P < 0.05 \), \( P < 0.01 \), and \( P < 0.01 \), resp.; Figure 4(a)).

Caspase-3 activity was increased by about 3.3-fold compared with untreated group after 6-OHDA exposure (\( P < 0.01 \)). In contrast, cotreatment with 1 \( \mu M \) and 10 \( \mu M \) of echinacoside showed a significant decrease in caspase-3 activity compared with 6-OHDA-treated cells, respectively (both \( P < 0.05 \) and Figure 4(b)).

PL is membrane permeability and is generally excluded from viable cells. So it is commonly used for identifying dead cells in a population. The results showed that the apoptosis rate was significantly increased following 24 h incubations with 100 \( \mu M \) 6-OHDA, whereas cotreatment with 1 and 10 \( \mu M \) echinacoside significantly reduced 6-OHDA-induced apoptosis (\( P < 0.05 \), \( P < 0.01 \), resp., Figure 4(c)).

3.4. Anti-Inflammatory Effect of Echinacoside in PC12 Cells Induced by 6-OHDA. The results showed that 6-OHDA exposure resulted in an increase in IL-1β level compared with untreated group (\( P < 0.05 \); Figure 4(a)). However, 10 \( \mu M \) of echinacoside could significantly reduce IL-1β release induced by 6-OHDA (\( P < 0.05 \); Figure 5(a)).

IL-6 level was also significantly increased compared with untreated group (\( P < 0.01 \)). However, cotreatment with 0.1, 1, and 10 \( \mu M \) of echinacoside all significantly decreased IL-6 release compared with 6-OHDA-treated cells (both \( P < 0.05 \) and Figure 5(b)).

3.5. Effect of ECH on ROS Production Induced by 6-OHDA in PC12 Cells. Cells treated with 6-OHDA showed a significant increase (about 1.4-fold) of intracellular ROS compared with untreated cells (\( P < 0.01 \)). This increase was significantly attenuated by coincubation with 0.1, 1, and 10 \( \mu M \) echinacoside (\( P < 0.05 \), \( P < 0.01 \), and \( P < 0.01 \), resp.; Figure 6).

4. Discussion

Echinacoside is one of the principal constituents of phenyl-ethanoid glycosides extracted from a famous traditional Chinese medicine, Herba Cistanches. Several studies have reported echinacoside has antiapoptotic and neuroprotective properties in neurodegenerative disease [18]. In vivo study reported that echinacoside had neuroprotective effects and behavioral improvement in the mouse model of MPTP-induced dopaminergic neuronal damage, while further investigation revealed that echinacoside induced downregulation of caspase-3 and caspase-8 activation in MPP⁺-induced apoptosis of cerebellar granule neurons [16]. Another in vivo study reported the neuroprotective effects of echinacoside on the striatal dopaminergic neurons injured by 6-OHDA [17]. However, the cellular and molecular mechanisms that underlie these actions are not fully understood, especially for their influence on mitochondrial function and inflammation responses. So our current study investigated the effects of echinacoside on mitochondrial function and inflammation responses to elucidate its mechanism against PD. The results firstly showed that echinacoside significantly alleviated 6-OHDA-induced neurotoxicity in PC12 cells through protecting mitochondrial function and anti-inflammation.

Mitochondrial dysfunction has long been implicated in the death of nigrostriatal dopaminergic neurons in Parkinson’s disease and its experimental models [26]. Mitochondria are deeply involved in the production of reactive oxygen species (ROS) through the electron carriers of the respiratory chain in neurodegenerative diseases [27]. A wide variety of ROS are produced in the course of the normal metabolism in biological systems, but their accumulation beyond the
Figure 2: Effect of echinacoside on morphological change and viability of PC12 cells injured by 6-OHDA. (A) Effect of different concentration of echinacoside on cell viability in PC12 cells. (B) Morphological changes induced by 6-OHDA treatment observed by light microscopy. Representative photographs: (a) untreated group; (b) 6-OHDA-treated group; (c) 6-OHDA+ echinacoside 0.1 μM; (d) 6-OHDA+ echinacoside 1 μM; and (e) 6-OHDA+ echinacoside 10 μM. (C) Effect of echinacoside on cell viability changes induced by 6-OHDA in PC12 cells. Data are expressed as percentage of untreated cells. Data are the mean ± SD, n = 4, #P < 0.01 versus untreated group; **P < 0.01 versus vehicle group.
required amount can potentially damage lipids, proteins, and nucleic acids.

6-OHDA, a catecholamine analogue, causes specific degeneration of substantia nigra neurons. Neurotoxicity induced by 6-OHDA is, in part, due to the production of ROS [28–32]. Previous studies have determined that treatment with 6-OHDA leads to neuronal death by affecting mitochondria function, including abatement in ATP production, disturbance of ROS metabolism, and the induction of apoptosis [10,33,34]. In the present study, our results also demonstrated that 6-OHDA damaged mitochondrial oxidative-reduction function, decreased mitochondrial membrane potential, induced mitochondria-mediated apoptosis, and increased ROS production in PC12 cells.

Resazurin is a fluorescent indicator that is intermediate only between final reductions of molecular oxygen and cytochrome oxidase. Therefore, the oxidative-reduction potential of resazurin allows the respiratory chain to function to near completion, which will provide a more accurate and sensitive indication of mitochondrial function. JC-1 is a membrane potential-sensitive probe that localizes to the inner mitochondrial membrane where it forms either monomers (green) or aggregates (red) based on mitochondrial membrane potential. Thus, resazurin and JC-1 are valuable analytical tools for examining mitochondrial function [35]. The present study indicated that decreases in mitochondrial oxidative-reduction activity and mitochondrial membrane potential may play important roles in 6-OHDA-induced dopaminergic neurotoxicity. Our result also showed that echinacoside alleviated 6-OHDA-induced decreases of mitochondrial oxidative-reduction activity and mitochondrial membrane potential. These results provide that that

**Figure 3:** Effect of echinacoside on mitochondrial dysfunction induced by 6-OHDA in PC12 cells. (a) ATP level; (b) mitochondrial oxidation-reduction activity; and (c) mitochondria membrane potential. Data are the mean ± SD, n = 4, **P < 0.01 versus untreated group; *P < 0.05, **P < 0.01 versus vehicle group.
Figure 4: Antimitochondria-mediated apoptotic effects of echinacoside in PC12 cells against 6-OHDA neurotoxicity. (A) Cytosolic cytochrome c release; (B) the activity of caspase-3; (C) apoptosis stained with PI by flow cytometric analysis. Representative photographs: (a) untreated group; (b) 6-OHDA-treated group; (c) 6-OHDA+ echinacoside 0.1 μM; (d) 6-OHDA+ echinacoside 1 μM; and (e) 6-OHDA+ echinacoside 10 μM. Data are the mean ± SD, n = 4, **P < 0.01 versus untreated group; *P < 0.05,** P < 0.01 versus vehicle group.
improvement of mitochondrial dysfunction may be a better way to slow progressive dopaminergic neurodegeneration commonly associated with PD.

It is generally accepted that cell apoptosis induced by 6-OHDA is mediated by mitochondrial dysfunction, characterized by cytochrome C release, and caspase-3 activation [36]. An apoptotic stimulus triggers the release of cytochrome C from the mitochondria into cytosol where it then activates caspase-3 and other downstream caspases. In the present study, the results showed that PC12 cells exposure to 100 µM of 6-OHDA enhanced cytochrome C release and caspase-3 activation. However, treatment with echinacoside dose dependently inhibited cytochrome C release and caspase-3 activation. These results suggest that echinacoside could inhibit mitochondria-mediated apoptosis through reducing cytochrome C release from mitochondria to cytosol and caspase-3 activation.

Inflammation is a neuropathological feature of Parkinsonian brains and also in experimental models of the disease. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these inflammatory factors may be a promising neuroprotective strategy for the treatment of Parkinson’s disease and related conditions [37]. Several studies also performed in the cerebrospinal fluid and during postmortem analysis in Parkinsonian patients revealed increased levels of cytokines, such as interleukin-1β (IL-1β) and interleukin-6 (IL-6), suggesting the activation of a proinflammatory response [38, 39]. In the present study, the results showed that exposure to 100 µM of 6-OHDA induced IL-1β and IL-6 release in PC12 cells. However, treatment with echinacoside could dose dependently inhibit IL-1β and IL-6 release induced by 6-OHDA. The results suggest that reducing inflammatory responses are also involved in the mechanisms of echinacoside against 6-OHDA-induced neurotoxicity.

In conclusion, the results of this research showed that echinacoside was able to block 6-OHDA-induced neurotoxicity in PC12 cells, and the mechanisms may be related to mitochondrial protection and anti-inflammation via reducing ROS production. Information provided by this work will be useful to elucidate the mechanism of echinacoside for anti-PD. It is concluded that echinacoside may be a promising therapeutic option for the prevention and treatment of PD.

**Conflict of Interests**

The authors have declared no conflict of interests.
Acknowledgments

This work was supported by Grants from the National Natural Science Foundation of China (81473383) and the National Science and Technology Major Project (2012ZX0910301-078; 2013ZX09103-001-008; and 2013ZX09102010).

References

[1] C. Noelker, M. Bacher, P. Gocke et al., “The flavanoid caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity,” Neuroscience Letters, vol. 383, no. 1-2, pp. 39–43, 2005.

[2] D. Blum, S. Torch, N. Lambeng et al., “Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease,” Progress in Neurobiology, vol. 65, no. 2, pp. 135–172, 2001.

[3] R. H. Swerdlow, “The neurodegenerative mitochondrialopathies,” Journal of Alzheimer’s Disease, vol. 17, no. 4, pp. 737–751, 2009.

[4] M. Karbowski, “Mitochondria on guard: role of mitochondrial fusion and fission in the regulation of apoptosis,” Advances in Experimental Medicine and Biology, vol. 687, pp. 131–142, 2010.

[5] Y. T. Shih, I. J. Chen, Y. C. Wu, and Y. C. Lo, “San-Huang-Xie-Xin-Tang protects against activated microglia- and 6-OHDA-induced toxicity in neuronal SH-SY5Y cells,” Evidence Based Complementary and Alternative Medicine, vol. 2011, Article ID 429384, 11 pages, 2011.

[6] B. S. Jeon, V. Jackson-Lewis, and R. E. Burke, “6-Hydroxydopamine lesion of the rat Substantia nigra: time course and morphology of cell death,” Neurodegeneration, vol. 4, no. 2, pp. 131–137, 1995.

[7] G. Nie, Y. Cao, and B. Zhao, “Protective effects of green tea polyphenols and their major component, (-)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells,” Redox Report, vol. 7, no. 3, pp. 171–177, 2002.

[8] G. Nie, C. Jin, Y. Cao, S. Shen, and B. Zhao, “Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells,” Archives of Biochemistry and Biophysics, vol. 397, no. 1, pp. 84–90, 2002.

[9] Y.-H. Wang, H.-T. Yu, X.-P. Pu, and G.-H. Du, “Baicalein prevents 6-hydroxydopamine-induced mitochondrial dysfunction in SH-SY5Y cells via inhibition of mitochondrial oxidation and up-regulation of DJ-1 protein expression,” Molecules, vol. 18, no. 12, pp. 14726–14738, 2013.

[10] Y.-H. Wang, Z.-H. Xuan, S. Tian, G.-R. He, and G.-H. Du, “Myricitrin attenuates 6-hydroxydopamine-induced mitochondrial damage and apoptosis in PC12 cells via inhibition of mitochondrial oxidation,” Journal of Functional Foods, vol. 5, no. 1, pp. 337–345, 2013.

[11] B. Fornstedt, E. Rosengren, and A. Carlsson, “Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species,” Neuropharmacology, vol. 25, no. 4, pp. 451–454, 1986.

[12] L. Lei, F. Q. Yang, T. Y. Zhang, P. Tu, L. Wu, and Y. Ito, “Preparative isolation and purification of acetoxe and 2-acetyl acetoxe from Cistanches salsa (C. Mey.) G. Beck by high-speed counter-current chromatography,” Journal of Chromatography A, vol. 912, no. 1, pp. 181–185, 2000.

[13] W. He, T. Fang, and P. Tu, “Research progress on pharmacological activities of echinacoside,” Zhongguo Zhong Yao Za Zhi, vol. 34, no. 4, pp. 476–479, 2009.

[14] Y. Li, Y.-Y. Song, and H.-Q. Zhang, “Effect of echinacoside on immune function and mitochondrial DNA relative content of aging mice,” Chinese Pharmacological Bulletin, vol. 26, no. 6, pp. 810–813, 2010.

[15] G. Mutelieu, L. Li, and P. F. Tu, “Study on molecular mechanism of echinacoside for aging against,” Acta Biophysica Sinica, vol. 20, no. 3, pp. 184–187, 2004.

[16] X. Geng, X. Tian, P. Tu, and X. Pu, “Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson’s disease,” European Journal of Pharmacology, vol. 564, no. 1–3, pp. 66–74, 2007.

[17] H. Chen, F. C. Jing, C. L. Li, P. F. Tu, Q. S. Zheng, and Z. H. Wang, “Echinacoside prevents the striatal extracellular levels of monoamine neurotransmitters from diminution in 6-hydroxydopamine lesion rats,” Journal of Ethnopharmacology, vol. 114, no. 3, pp. 285–289, 2007.

[18] M. Deng, J. Y. Zhao, P. F. Tu, Y. Jiang, Z. B. Li, and Y. H. Wang, “Echinacoside rescues the SH-SY5Y neuronal cells from TNFalpha-induced apoptosis,” European Journal of Pharmacology, vol. 505, no. 1–3, pp. 11–18, 2004.

[19] Y.-H. Wang and G.-H. Du, “Ginsenoside Rgl inhibits β-secretase activity in vitro and protects against Aβ42-induced cytotoxicity in PC12 cells,” Journal of Asian Natural Products Research, vol. 11, no. 7, pp. 604–612, 2009.

[20] M. A. Tirmenstein, C. X. Hu, M. S. Scicchitano et al., “Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells,” Toxicology in Vitro, vol. 19, no. 4, pp. 471–479, 2005.

[21] Y.-H. Wang, H.-T. Yu, Y.-P. Han, X.-P. Pu, and G.-H. Du, “Protocatechualedehyde prevents methylglyoxal-induced mitochondrial dysfunction and AGES-RAGE axis activation in human lens epithelial cells,” European Journal of Pharmacology, vol. 738, no. 6, pp. 374–383, 2014.

[22] Y.-H. Wang, H.-T. Yu, X.-P. Pu, and G.-H. Du, “Myricitrin alleviates methylglyoxal-induced mitochondrial dysfunction and AGES/RAGE/NF-kB pathway activation in SH-SY5Y cells,” Journal of Molecular Neuroscience, vol. 53, no. 4, pp. 562–570, 2014.

[23] R. A. Eliseev, I. Malecki, T. Lester, Y. Zhang, J. Humphrey, and T. E. Gunter, “Cyclophilin D interacts with Bcl3, and exerts an anti-apoptotic effect,” The Journal of Biological Chemistry, vol. 284, no. 15, pp. 9692–9699, 2009.

[24] C. Hermann, A. M. Zeiher, and S. Dimmeler, “Shear stress inhibits H2O2-induced apoptosis of human endothelial cells by modulation of the glutathione redox cycle and nitric oxide synthase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 12, pp. 3588–3592, 1997.

[25] D.-S. Hwang, H. G. Kim, H.-J. Kwon et al., “Danggugjakyak-san, a medicinal herbal formula, protects dopaminergic neurons from 6-hydroxydopamine-induced neurotoxicity,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 934–939, 2011.

[26] A. H. V. Schapira, “Mitochondrial dysfunction in neurodegenerative disorders,” Biochimica et Biophysica Acta: Bioenergetics, vol. 1366, no. 1-2, pp. 225–233, 1998.

[27] M. F. Beal, “Parkinson’s disease: a model dilemma,” Nature, vol. 466, no. 7310, pp. S8–S10, 2010.

[28] B. Feger, C. Themann, S. Rose, B. Halliwell, and P. Jenner, “6-Hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation,” Journal of Neurochemistry, vol. 78, no. 3, pp. 509–514, 2001.

[29] E. Mendoza-Álvarez, R. Soto-Otero, Á. Hermida-Ameijeiras, M. E. López-Martín, and J. L. Labandeira-Garcia, “Effect of...” Evidence-Based Complementary and Alternative Medicine
iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants," *Free Radical Biology and Medicine*, vol. 31, no. 8, pp. 986–998, 2001.

[30] Z. Ma, X. Wei, C. Fontanilla et al., "Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity," *Life Sciences*, vol. 79, no. 13, pp. 1307–1311, 2006.

[31] J. C. Bensadoun, O. Mirochnitchenko, M. Inouye, P. Aeischer, and A. D. Zurn, "Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice," *European Journal of Neuroscience*, vol. 10, no. 10, pp. 3231–3236, 1998.

[32] B. Ferger, P. Teismann, and J. Mierau, "The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study," *Brain Research*, vol. 883, no. 2, pp. 216–223, 2000.

[33] K. Prokai-Tatrai and L. Prokai, "Impact of metabolism on the safety of estrogen therapy," *Annals of the New York Academy of Sciences*, vol. 1052, no. 6, pp. 243–257, 2005.

[34] K. Sas, H. Robotka, J. Toldi, and L. Vécsei, "Mitochondria, metabolic disturbances, oxidative stress and the kynurenic system, with focus on neurodegenerative disorders," *Journal of the Neurological Sciences*, vol. 257, no. 1–2, pp. 221–239, 2007.

[35] M. Nakai, A. Mori, A. Watanabe, and Y. Mitsumoto, "1-Methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (ΔΨm) in rat striatum," *Experimental Neurology*, vol. 179, no. 1, pp. 103–110, 2003.

[36] Y. Saito, K. Nishio, Y. Ogawa et al., "Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action," *Free Radical Biology and Medicine*, vol. 42, no. 5, pp. 675–685, 2007.

[37] S. Przedborski, "Inflammation and Parkinson's disease pathogenesis," *Movement Disorders*, vol. 25, supplement 1, pp. S55–S57, 2010.

[38] C. Barcia, A. F. Barreiro, M. Poza, and M.-T. Herrero, "Parkinson's disease and inflammatory changes," *Neurotoxicity Research*, vol. 5, no. 6, pp. 411–417, 2003.

[39] M. Mogi, M. Harada, T. Kondo et al., "Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients," *Neuroscience Letters*, vol. 180, no. 2, pp. 147–150, 1994.